Gianpaolo Marcacci

Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia

Giovanni D’Arena, Luca Laurenti, Silvana Capalbo et al. · American Journal of Hematology · 2006 · 103 citations · Full text

Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma

Gaetano Corazzelli, Gaetana Capobianco, Manuela Arcamone et al. · Cancer Chemotherapy and Pharmacology · 2009 · 75 citations

B-cell Lymphoma, Lymphoid Neoplasia, Hematological Malignancy +8

Biweekly rituximab, cyclophosphamide, vincristine, non‐pegylated liposome‐encapsulated doxorubicin and prednisone (R‐COMP‐14) in elderly patients with poor‐risk diffuse large B‐cell lymphoma and moderate to high ‘life threat’ impact cardiopathy

Gaetano Corazzelli, Ferdinando Frigeri, Manuela Arcamone et al. · British Journal of Haematology · 2011 · 58 citations · Full text

Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study

Maurizio Musso, Renato Scalone, Gianpaolo Marcacci et al. · Bone Marrow Transplantation · 2009 · 43 citations · Full text

Lymphoid Neoplasia, Oncology, Multicenter Feasibility Study +5

Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study

Gaetano Corazzelli, Filippo Russo, Giampiero Capobianco et al. · Annals of Oncology · 2006 · 41 citations · Full text

Lymphoid Neoplasia, Refractory Aggressive Non-hodgkin, Medicine +7